Client CURE Pharmaceutical was featured on Seeking Alpha for their groundbreaking study on cannabinoids as a treatment for cancer. The article featured background on the company as well as highlighted their recent partnership with Israeli researcher Technion and the beginnings of their clinical research.

CURE Pharmaceutical (OTCQB:CURR) is kicking off a first-ever clinical study to research cannabinoid compounds to treat leukemia and prostate cancer. Specifically, the company, along with its partner Technion – Israel Institute of Technology, will be testing to see if these cannabinoid molecules will attack tumorous cancer cells.

Read the Full Article HERE